TOP TEN perturbations for Q9H6U6 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9H6U6
Selected probe(set): 220488_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9H6U6 (220488_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

frataxin polyamide study 3 (FRDA; mismatch) / frataxin polyamide study 6 (mismatch)

Relative Expression (log2-ratio):2.321187
Number of Samples:3 / 2
Experimental frataxin polyamide study 3 (FRDA; mismatch)
Lymphoblastoid cells derived from a patient with Freidriech's Ataxia (FRDA, Coriell repository ID: GM15850) were incubated with the mismatch polyamide (FA2) targeting FXN (frataxin) at 2uM for 7days prior to RNA purification and microarray analysis. The patient carries homozygous GAA expansion in the FXN (frataxin) gene with alleles of approximately 650 and 1030 repeats. Clinical image: ataxia, scoliosis, hypertrophic cardiomyopathy, slurred speech.
Control frataxin polyamide study 6 (mismatch)
Lymphoblastoid cells derived from normal healthy subject (Coriell repository ID: GM15851) were incubated with the mismatch polyamide (FA2) targeting FXN (frataxin) at 2uM for 7days prior to RNA purification and microarray analysis.

polyamide study 1 (mismatch) / dexamethasone study 8

Relative Expression (log2-ratio):-2.0098915
Number of Samples:3 / 3
Experimental polyamide study 1 (mismatch)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a mismatched synthetic DNA-binding polyamide (normally targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control dexamethasone study 8
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:, , , , , , , , , ,

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):1.943347
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

polyamide study 1 (mismatch) / mifepristone study 4

Relative Expression (log2-ratio):-1.8740826
Number of Samples:3 / 3
Experimental polyamide study 1 (mismatch)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a mismatched synthetic DNA-binding polyamide (normally targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control mifepristone study 4
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3?M of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:

CH5183284 study 1 (KATO-III) / vehicle (DMSO) treated KATO-III cell sample

Relative Expression (log2-ratio):1.8283167
Number of Samples:2 / 2
Experimental CH5183284 study 1 (KATO-III)
Human gastric cell line KATO-III treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated KATO-III cell sample
Human gastric cell line KATO-III treated with 0.1% DMSO for 24 hours.

polyamide study 1 (match) / dexamethasone study 8

Relative Expression (log2-ratio):-1.8244991
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control dexamethasone study 8
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:, , , , , , , , , ,

polyamide study 1 (mismatch) / vehicle (medium) treated A549 cell sample

Relative Expression (log2-ratio):-1.7634621
Number of Samples:3 / 3
Experimental polyamide study 1 (mismatch)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a mismatched synthetic DNA-binding polyamide (normally targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control vehicle (medium) treated A549 cell sample
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. Samples were taken after additional 56 hours.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / monocyte activation study 1 (NOD2L/TLR/1L; 6h)

Relative Expression (log2-ratio):1.7449732
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control monocyte activation study 1 (NOD2L/TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).

polyamide study 1 (match) / mifepristone study 4

Relative Expression (log2-ratio):-1.6886902
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control mifepristone study 4
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3?M of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:

cisplatin study 4 (20uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):-1.6472702
Number of Samples:3 / 12
Experimental cisplatin study 4 (20uM)
HepG2 cells treated with compound: cisplatin (20uM; CAS no.:15663-27-1) for 24 hours. Cisplatin is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.